{"pmid":32480420,"title":"Challenges in the Management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.","text":["Challenges in the Management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.","The SARS-CoV-2-associated disease (COVID-19) is primarily manifested as a respiratory tract infection but may affect and cause complications from multiple organ systems (cardiovascular, gastrointestinal, kidneys, hematopoietic and immune systems) while no proven specific therapy exists. The challenges associated with COVID-19 are even greater for patients with light chain (AL) amyloidosis, a rare multisystemic disease affecting the heart, kidneys, liver, gastrointestinal and nervous system. Patients with AL amyloidosis may need to receive chemotherapy, which probably increases infection risk. Management of COVID-19 may be particularly challenging in patients with AL amyloidosis who often present with cardiac dysfunction, nephrotic syndrome, neuropathy, low blood pressure and gastrointestinal symptoms. In addition, AL patients may be more susceptible to toxicities of drugs used to manage COVID-19. Access to health care may be difficult or limited, diagnosis of AL amyloidosis may be delayed with detrimental consequences, treatment administration may need modification. Both patients and treating physicians need to adapt in a new reality.","Br J Haematol","Kastritis, Efstathios","Wechalekar, Ashutosh","Schonland, Stefan","Sanchorawala, Vaishali","Merlini, Giampaolo","Palladini, Giovanni","Minnema, Monique","Roussel, Murielle","Jaccard, Arnaud","Hegenbart, Ute","Kumar, Shaji","Cibeira, Maria Teresa","Blade, Joan","Dimopoulos, Meletios A","32480420"],"abstract":["The SARS-CoV-2-associated disease (COVID-19) is primarily manifested as a respiratory tract infection but may affect and cause complications from multiple organ systems (cardiovascular, gastrointestinal, kidneys, hematopoietic and immune systems) while no proven specific therapy exists. The challenges associated with COVID-19 are even greater for patients with light chain (AL) amyloidosis, a rare multisystemic disease affecting the heart, kidneys, liver, gastrointestinal and nervous system. Patients with AL amyloidosis may need to receive chemotherapy, which probably increases infection risk. Management of COVID-19 may be particularly challenging in patients with AL amyloidosis who often present with cardiac dysfunction, nephrotic syndrome, neuropathy, low blood pressure and gastrointestinal symptoms. In addition, AL patients may be more susceptible to toxicities of drugs used to manage COVID-19. Access to health care may be difficult or limited, diagnosis of AL amyloidosis may be delayed with detrimental consequences, treatment administration may need modification. Both patients and treating physicians need to adapt in a new reality."],"journal":"Br J Haematol","authors":["Kastritis, Efstathios","Wechalekar, Ashutosh","Schonland, Stefan","Sanchorawala, Vaishali","Merlini, Giampaolo","Palladini, Giovanni","Minnema, Monique","Roussel, Murielle","Jaccard, Arnaud","Hegenbart, Ute","Kumar, Shaji","Cibeira, Maria Teresa","Blade, Joan","Dimopoulos, Meletios A"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32480420","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/bjh.16898","topics":["Prevention"],"weight":1,"_version_":1668437835096522752,"score":9.490897,"similar":[{"pmid":32364264,"title":"Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction.","text":["Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction.","AIMS: Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly evolved into a sweeping pandemic. While its major manifestation is in the respiratory tract, the general extent of organ involvement as well as microscopic changes in the lungs remain insufficiently characterised. Autopsies are essential to elucidate COVID-19-associated organ alterations. METHODS: This study reports autopsy findings of 21 COVID-19 patients hospitalised at the University Hospital Basel and at the Cantonal Hospital Baselland, Switzerland. An in-corpore technique was performed to ensure optimal staff safety. RESULTS: The primary cause of death was respiratory failure with exudative diffuse alveolar damage with massive capillary congestion often accompanied by microthrombi despite anticoagulation. Ten cases showed superimposed bronchopneumonia. Further findings included pulmonary embolisms (n=4), alveolar haemorrhage (n=3) and vasculitis (n=1). Pathologies in other organ systems were predominantly attributable to shock; three patients showed signs of generalised thrombotic microangiopathy. Six patients were diagnosed with senile cardiac amyloidosis upon autopsy. Most patients suffered from one or more comorbidities (hypertension, obesity, cardiovascular diseases, diabetes mellitus). Additionally, there was an overall predominance of males and individuals with blood group A (81% and 65%, respectively). All relevant histological slides are linked as open-source scans in supplementary files. CONCLUSIONS: This study provides an overview of post-mortem findings in COVID-19 cases, implying that hypertensive, elderly, obese, male individuals with severe cardiovascular comorbidities as well as those with blood group A may have a lower threshold of tolerance for COVID-19. This provides a pathophysiological explanation for higher mortality rates amongst these patients.","Histopathology","Menter, T","Haslbauer, J D","Nienhold, R","Savic, S","Hopfer, H","Deigendesch, N","Frank, S","Turek, D","Willi, N","Pargger, H","Bassetti, S","Leuppi, J D","Cathomas, G","Tolnay, M","Mertz, K D","Tzankov, A","32364264"],"abstract":["AIMS: Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly evolved into a sweeping pandemic. While its major manifestation is in the respiratory tract, the general extent of organ involvement as well as microscopic changes in the lungs remain insufficiently characterised. Autopsies are essential to elucidate COVID-19-associated organ alterations. METHODS: This study reports autopsy findings of 21 COVID-19 patients hospitalised at the University Hospital Basel and at the Cantonal Hospital Baselland, Switzerland. An in-corpore technique was performed to ensure optimal staff safety. RESULTS: The primary cause of death was respiratory failure with exudative diffuse alveolar damage with massive capillary congestion often accompanied by microthrombi despite anticoagulation. Ten cases showed superimposed bronchopneumonia. Further findings included pulmonary embolisms (n=4), alveolar haemorrhage (n=3) and vasculitis (n=1). Pathologies in other organ systems were predominantly attributable to shock; three patients showed signs of generalised thrombotic microangiopathy. Six patients were diagnosed with senile cardiac amyloidosis upon autopsy. Most patients suffered from one or more comorbidities (hypertension, obesity, cardiovascular diseases, diabetes mellitus). Additionally, there was an overall predominance of males and individuals with blood group A (81% and 65%, respectively). All relevant histological slides are linked as open-source scans in supplementary files. CONCLUSIONS: This study provides an overview of post-mortem findings in COVID-19 cases, implying that hypertensive, elderly, obese, male individuals with severe cardiovascular comorbidities as well as those with blood group A may have a lower threshold of tolerance for COVID-19. This provides a pathophysiological explanation for higher mortality rates amongst these patients."],"journal":"Histopathology","authors":["Menter, T","Haslbauer, J D","Nienhold, R","Savic, S","Hopfer, H","Deigendesch, N","Frank, S","Turek, D","Willi, N","Pargger, H","Bassetti, S","Leuppi, J D","Cathomas, G","Tolnay, M","Mertz, K D","Tzankov, A"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32364264","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/his.14134","keywords":["sars-cov-2","autopsy","cardiovascular","lung","senile amyloidosis"],"locations":["Switzerland","obese"],"countries":["Switzerland"],"countries_codes":["CHE|Switzerland"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138496042008577,"score":226.51337},{"pmid":32450197,"title":"Extra-respiratory manifestations of COVID-19.","text":["Extra-respiratory manifestations of COVID-19.","Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global health threat. Although most patients with COVID-19 manifest fever and respiratory tract symptoms, SARS-CoV-2 infection may also involve other organs/systems and present with extra-respiratory manifestations, including cardiac, gastrointestinal, hepatic, renal, neurological, olfactory, gustatory, ocular, cutaneous and haematological symptoms. Occasionally, these extra-respiratory symptoms/signs represent the initial presentation of SARS-CoV-2 infection, prior to fever or respiratory manifestations. Therefore, this comprehensive review of the extra-respiratory manifestations of COVID-19 is intended to help clinicians better understand the range of clinical presentations associated with SARS-CoV-2 infection, allowing the consideration of COVID-19 in differential diagnoses. A screening test for SARS-CoV-2 should be performed when patients have these extra-respiratory manifestations. In addition, clinicians should be alerted to the adverse effects of anti-SARS-CoV-2 agents that can mimic the extra-respiratory manifestations of COVID-19. Moreover, some extra-respiratory manifestations, such as ocular and gastrointestinal involvement, may be caused by direct invasion of SARS-CoV-2. Therefore, protective measures should be taken while managing the associated clinical specimens. Finally, several extra-respiratory manifestations, such as cardiac involvement, acute kidney injury, coagulation disorders and thrombotic complications, could be associated with a poor prognosis.","Int J Antimicrob Agents","Lai, Chih-Cheng","Ko, Wen-Chien","Lee, Ping-Ing","Jean, Shio-Shin","Hsueh, Po-Ren","32450197"],"abstract":["Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global health threat. Although most patients with COVID-19 manifest fever and respiratory tract symptoms, SARS-CoV-2 infection may also involve other organs/systems and present with extra-respiratory manifestations, including cardiac, gastrointestinal, hepatic, renal, neurological, olfactory, gustatory, ocular, cutaneous and haematological symptoms. Occasionally, these extra-respiratory symptoms/signs represent the initial presentation of SARS-CoV-2 infection, prior to fever or respiratory manifestations. Therefore, this comprehensive review of the extra-respiratory manifestations of COVID-19 is intended to help clinicians better understand the range of clinical presentations associated with SARS-CoV-2 infection, allowing the consideration of COVID-19 in differential diagnoses. A screening test for SARS-CoV-2 should be performed when patients have these extra-respiratory manifestations. In addition, clinicians should be alerted to the adverse effects of anti-SARS-CoV-2 agents that can mimic the extra-respiratory manifestations of COVID-19. Moreover, some extra-respiratory manifestations, such as ocular and gastrointestinal involvement, may be caused by direct invasion of SARS-CoV-2. Therefore, protective measures should be taken while managing the associated clinical specimens. Finally, several extra-respiratory manifestations, such as cardiac involvement, acute kidney injury, coagulation disorders and thrombotic complications, could be associated with a poor prognosis."],"journal":"Int J Antimicrob Agents","authors":["Lai, Chih-Cheng","Ko, Wen-Chien","Lee, Ping-Ing","Jean, Shio-Shin","Hsueh, Po-Ren"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32450197","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.ijantimicag.2020.106024","keywords":["covid-19","epidemiology","extra-respiratory manifestations","sars-cov-2"],"locations":["gustatory","clinicians","clinicians"],"topics":["Treatment","Diagnosis","Mechanism","Prevention"],"weight":1,"_version_":1667785213917265920,"score":174.20114},{"pmid":32501876,"title":"Implications of COVID-19 for the busy gastroenterologist.","text":["Implications of COVID-19 for the busy gastroenterologist.","Coronavirus disease 2019 (COVID-19) is an infection caused by a novel coronavirus (SARS-CoV-2) originated in China in December 2020 and declared pandemic by WHO. This coronavirus mainly spreads through the respiratory tract and enters cells through angiotensin-converting enzyme 2 (ACE2). The clinical symptoms of COVID-19 patients include fever, cough, and fatigue. Gastrointestinal symptoms (diarrhea, anorexia, and vomiting) may be present in 50% of patients and may be associated with worst prognosis. Other risk factors are older age, male gender, and underlying chronic diseases. Mitigation measures are essential to reduce the number of people infected. Hospitals are a place of increased SARS-CoV-2 exposure. This has implications in the organization of healthcare services and specifically endoscopy departments. Patients and healthcare workers safety must be optimized in this new reality. Comprehension of COVID-19 gastrointestinal manifestations and implications of SARS-CoV-2 in the management of patients with gastrointestinal diseases, under or not immunosuppressant therapies, is essential. In this review, we summarized the latest research progress and major societies recommendations regarding the implications of COVID-19 in gastroenterology, namely the adaptations that gastroenterology/endoscopy departments and professionals must do in order to optimize the provided assistance, as well as the implications that this infection will have, in particularly vulnerable patients such as those with chronic liver disease and inflammatory bowel disease under or not immunosuppressant therapies.","Eur J Gastroenterol Hepatol","Ferreira-Silva, Joel","Peixoto, Armando","Rodrigues-Pinto, Eduardo","Macedo, Guilherme","32501876"],"abstract":["Coronavirus disease 2019 (COVID-19) is an infection caused by a novel coronavirus (SARS-CoV-2) originated in China in December 2020 and declared pandemic by WHO. This coronavirus mainly spreads through the respiratory tract and enters cells through angiotensin-converting enzyme 2 (ACE2). The clinical symptoms of COVID-19 patients include fever, cough, and fatigue. Gastrointestinal symptoms (diarrhea, anorexia, and vomiting) may be present in 50% of patients and may be associated with worst prognosis. Other risk factors are older age, male gender, and underlying chronic diseases. Mitigation measures are essential to reduce the number of people infected. Hospitals are a place of increased SARS-CoV-2 exposure. This has implications in the organization of healthcare services and specifically endoscopy departments. Patients and healthcare workers safety must be optimized in this new reality. Comprehension of COVID-19 gastrointestinal manifestations and implications of SARS-CoV-2 in the management of patients with gastrointestinal diseases, under or not immunosuppressant therapies, is essential. In this review, we summarized the latest research progress and major societies recommendations regarding the implications of COVID-19 in gastroenterology, namely the adaptations that gastroenterology/endoscopy departments and professionals must do in order to optimize the provided assistance, as well as the implications that this infection will have, in particularly vulnerable patients such as those with chronic liver disease and inflammatory bowel disease under or not immunosuppressant therapies."],"journal":"Eur J Gastroenterol Hepatol","authors":["Ferreira-Silva, Joel","Peixoto, Armando","Rodrigues-Pinto, Eduardo","Macedo, Guilherme"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32501876","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1097/MEG.0000000000001811","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1668890966342238210,"score":173.59367},{"pmid":32425338,"pmcid":"PMC7233216","title":"Extrapulmonary manifestations of COVID-19: Radiologic and clinical overview.","text":["Extrapulmonary manifestations of COVID-19: Radiologic and clinical overview.","COVID-19 is principally a respiratory illness and pulmonary manifestations constitute main presentations of the disease. According to the reported studies, SARS-CoV-2 infection is not limited to the respiratory system and other organs can be also affected. Renal dysfunction, gastrointestinal complications, liver dysfunction, cardiac manifestations, mediastinal findings, neurological abnormalities, and hematological manifestations are among the reported extrapulmonary features. Considering the broad spectrum of clinical manifestations and the increasing worldwide burden of the disease, there is an urgent need to rapidly scale up the diagnostic capacity to detect COVID-19 and its complications. This paper focuses on the most common extrapulmonary manifestations in patients with COVID-19 pneumonia. Further studies are needed to elaborate and confirm the causative relationship between SARS-CoV-2 and the reported extrapulmonary manifestations of COVID-19.","Clin Imaging","Behzad, Shima","Aghaghazvini, Leila","Radmard, Amir Reza","Gholamrezanezhad, Ali","32425338"],"abstract":["COVID-19 is principally a respiratory illness and pulmonary manifestations constitute main presentations of the disease. According to the reported studies, SARS-CoV-2 infection is not limited to the respiratory system and other organs can be also affected. Renal dysfunction, gastrointestinal complications, liver dysfunction, cardiac manifestations, mediastinal findings, neurological abnormalities, and hematological manifestations are among the reported extrapulmonary features. Considering the broad spectrum of clinical manifestations and the increasing worldwide burden of the disease, there is an urgent need to rapidly scale up the diagnostic capacity to detect COVID-19 and its complications. This paper focuses on the most common extrapulmonary manifestations in patients with COVID-19 pneumonia. Further studies are needed to elaborate and confirm the causative relationship between SARS-CoV-2 and the reported extrapulmonary manifestations of COVID-19."],"journal":"Clin Imaging","authors":["Behzad, Shima","Aghaghazvini, Leila","Radmard, Amir Reza","Gholamrezanezhad, Ali"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425338","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.clinimag.2020.05.013","keywords":["covid-19","extrapulmonary manifestation","gastrointestinal complications","liver dysfunction","lymphadenopathy","neurological manifestations","pericardial effusion","renal dysfunction","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1667352728680005632,"score":167.26305},{"pmid":32406522,"title":"COVID-19: focus on the lungs but do not forget the gastrointestinal tract.","text":["COVID-19: focus on the lungs but do not forget the gastrointestinal tract.","The coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared in the last weeks as the global pandemics. Currently affecting more than 3,000,000 individuals worldwide, COVID-19 is most commonly associated with symptoms caused by the acute respiratory distress syndrome (ARDS). As the number of infected individuals increases, we are learning that not only lungs, but also other organs can be affected by the virus. The gastrointestinal symptoms, like for example diarrhoea, vomiting, nausea, or abdominal pain are frequent in patients with COVID-19. Moreover, alimentary tract symptoms may precede the respiratory presentation of SARS-CoV-2 infection. This can lead to delayed diagnosis and inappropriate management of infected patients. In addition, SARS-CoV-2 nucleic acid can be detected in faeces of infected patients and rectal swabs are even reported to remain positive for a longer period of time than nasopharyngeal swabs. Here, we aim to provide an update on the gastrointestinal involvement of COVID-19 presenting the symptoms that can be encountered in infected patients. We address the role of ACE2, as a functional receptor for SARS-CoV-2, which also was found in the gastrointestinal tract. Finally, we briefly discuss faecal shedding of SARS-CoV-2 and its potential role in the pathogenesis of the disease.","Eur J Clin Invest","Smyk, Wiktor","Janik, Maciej K","Portincasa, Piero","Milkiewicz, Piotr","Lammert, Frank","Krawczyk, Marcin","32406522"],"abstract":["The coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared in the last weeks as the global pandemics. Currently affecting more than 3,000,000 individuals worldwide, COVID-19 is most commonly associated with symptoms caused by the acute respiratory distress syndrome (ARDS). As the number of infected individuals increases, we are learning that not only lungs, but also other organs can be affected by the virus. The gastrointestinal symptoms, like for example diarrhoea, vomiting, nausea, or abdominal pain are frequent in patients with COVID-19. Moreover, alimentary tract symptoms may precede the respiratory presentation of SARS-CoV-2 infection. This can lead to delayed diagnosis and inappropriate management of infected patients. In addition, SARS-CoV-2 nucleic acid can be detected in faeces of infected patients and rectal swabs are even reported to remain positive for a longer period of time than nasopharyngeal swabs. Here, we aim to provide an update on the gastrointestinal involvement of COVID-19 presenting the symptoms that can be encountered in infected patients. We address the role of ACE2, as a functional receptor for SARS-CoV-2, which also was found in the gastrointestinal tract. Finally, we briefly discuss faecal shedding of SARS-CoV-2 and its potential role in the pathogenesis of the disease."],"journal":"Eur J Clin Invest","authors":["Smyk, Wiktor","Janik, Maciej K","Portincasa, Piero","Milkiewicz, Piotr","Lammert, Frank","Krawczyk, Marcin"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32406522","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/eci.13276","keywords":["coronavirus","sars-cov-2","diarrhoea","faecal-oral transmission","gallbladder"],"topics":["Mechanism","Diagnosis"],"weight":1,"_version_":1666950579769835520,"score":152.67397}]}